Minapharm Pharmaceuticals results, Q2 2024
Net profit, assets, equity and cash flow for Q2 2024, against the same period a year earlier, from the published financial statements.
Net profit157 millionEGP · +591.0% vs the same period a year earlier
Total assets12 billionEGP · +37.9% vs the same period a year earlier
Shareholders' equity4.41 billionEGP · +25.4% vs the same period a year earlier
Operating cash flow222 millionEGP · +109.6% vs the same period a year earlier
In short
- Minapharm Pharmaceuticals's net profit for Q2 2024 was about 157 million EGP, up +591.0% from -31.99 million EGP in Q2 2023.
- Total assets at the end of Q2 2024 were about 12 billion EGP, and shareholders' equity about 4.41 billion EGP.
- Operating cash flow for Q2 2024 was positive at 222 million EGP.
Key lines against the same period a year earlier
This periodQ2 2023Change
Net profit157 million-31.99 million+591.0%
Gross profit917 million1.41 billion−34.8%
Total assets12 billion8.7 billion+37.9%
Total liabilities7.59 billion5.19 billion+46.4%
Shareholders' equity4.41 billion3.52 billion+25.4%
Total liabilities and equity12 billion8.7 billion+37.9%
Operating cash flow222 million106 million+109.6%
Investing cash flow-574 million-1.41 billion+59.3%
Financing cash flow1.32 billion1.51 billion−13.0%
Net change in cash964 million209 million+360.9%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Minapharm Pharmaceuticals's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy